argenx (ARGX) Stock Forecast & Price Target

$586.30

+34.59 (+6.27%)

(As of 10/31/2024 ET)

argenx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
4

Buy
18

Based on 22 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$557.11
-4.98% Downside

According to the 22 analysts' twelve-month price targets for argenx, the average price target is $557.11. The highest price target for ARGX is $660.00, while the lowest price target for ARGX is $408.00. The average price target represents a forecasted downside of -4.98% from the current price of $586.30.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenx and its competitors.

ARGX Analyst Ratings Over Time

Type	Current Forecast 11/1/23 to 10/31/24	1 Month Ago 10/2/23 to 10/1/24	3 Months Ago 8/3/23 to 8/2/24	1 Year Ago 11/1/22 to 11/1/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	17 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$557.11	$547.74	$540.37	$547.11
Forecasted Upside	-4.98% Downside	0.08% Upside	8.15% Upside	10.58% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenx Stock vs. The Competition

Type	argenx	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	-6.39% Downside	15,773.04% Upside	10.09% Upside
News Sentiment Rating	Positive News See Recent ARGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/31/2024	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$540.00 ➝ $660.00	+13.91%
10/17/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$512.00 ➝ $635.00	+16.89%
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%
10/4/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/26/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$585.00 ➝ $585.00	+9.45%
8/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$500.00 ➝ $640.00	+23.16%
Get the Latest News and Ratings for ARGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.
8/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Pitman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/29/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$490.00 ➝ $515.00	+4.15%
7/26/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$519.00 ➝ $560.00	+13.62%
7/26/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$543.00 ➝ $547.00	+13.93%
7/26/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$504.00 ➝ $533.00	+9.60%
7/23/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$546.00 ➝ $546.00	+18.44%
7/12/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$478.00 ➝ $533.00	+15.44%
6/24/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$535.00 ➝ $607.00	+40.57%
6/24/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$485.00 ➝ $500.00	+14.82%
6/24/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$522.00 ➝ $535.00	+35.63%
6/17/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/28/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$515.00 ➝ $510.00	+39.29%
5/10/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$471.00 ➝ $468.00	+25.62%
3/26/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$402.00 ➝ $408.00	+2.40%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$612.00 ➝ $641.00	+41.35%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$605.00 ➝ $628.00	+29.56%
7/24/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$480.00 ➝ $570.00	+3.93%
6/15/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$430.00 ➝ $435.00	+25.00%
3/3/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$430.00 ➝ $435.00	+26.07%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$441.00 ➝ $458.00	+19.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:47 PM ET.

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 10, 2024. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

argenx
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

argenx SE has received positive ratings from multiple analysts, with a consensus price target of $547.74, indicating potential for growth.
Recent institutional trading activity shows increased stake by large investors, reflecting confidence in the company's future performance.
argenx SE reported earnings per share of $0.45 for the quarter, surpassing analyst estimates by a significant margin, demonstrating strong financial performance.
Analysts have upgraded their price targets for argenx SE, with several firms giving a "buy" or "outperform" rating, suggesting a positive outlook for the stock.
argenx SE's stock price has been trading up, showing a 0.4% increase, with a market cap of $32.17 billion, indicating investor interest and potential value.

argenx
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

argenx SE has a negative return on equity of 7.33% and a negative net margin of 12.31%, indicating potential financial risks and challenges.
The company is forecasted to post a negative EPS of -0.37 for the current year, which may raise concerns about its profitability and future earnings.
While analysts have given positive ratings, there is always a risk of market volatility and unforeseen events impacting the stock price of argenx SE.
Investing in biotechnology companies like argenx SE carries inherent risks due to the nature of drug development and regulatory approvals, which can lead to uncertainties in returns.
The stock's price-to-earnings ratio of -95.05 and a beta of 0.62 may indicate volatility and potential overvaluation, posing risks for investors.

ARGX Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $557.11, with a high forecast of $660.00 and a low forecast of $408.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
: According to analysts, argenx's stock has a predicted downside of -4.98% based on their 12-month stock forecasts.
: Over the previous 90 days, argenx's stock had 1 upgrade and 1 downgrade by analysts.
: argenx has been rated by research analysts at Barclays, Citigroup, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Raymond James, and Truist Financial in the past 90 days.
: Analysts like argenx more than other "medical" companies. The consensus rating score for argenx is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (NASDAQ:ARGX) was last updated on 10/31/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenx (ARGX) Stock Forecast & Price Target